Copyright 2017 Shandong Galaxy Bio-Tech Co., Ltd. ICP14014899
Shandong Galaxy Bio-Tech Co., Ltd.
Add:NO.16,Quanfu Road, Economic Development Zone,SiShui,ShanDong Prov.,China
North America Office
Contact:Mr. John Huang
Add: 57 Starboard Dr. Halifax,NovaScotia, Canada, B3M 4T2
WeChat service number
Shandong Galaxy Bio-Tech Co., Ltd and Wuhan Qirui Pharmaceutical Strategic Cooperation Signing Ceremony Completed Successfully
On December 1, 2017, Shandong Galaxy Bio-Tech Co., Ltd. and Shanghai Meiyue Bio-Technology Development Co., Ltd. reached a strategic cooperation agreement in Wuhan Qirui Pharmaceutical Headquarters. Shanghai Meiyue Biotechnology Development Co., Ltd. is a wholly-owned subsidiary of Wuhan Qirui Pharmaceutical. Established in September 2005, Wuhan Qirui Pharmaceutical Co., Ltd. is located in Miaoshan Medical Park, Wuhan East Lake Development Zone. It is a national high-tech pharmaceutical company that integrates science, industry, and trade with pharmaceutical research and development. He successively undertook 7 major national science and technology major projects for "major new drug creation", and the Ministry of Science and Technology University personnel service company projects, the National Development and Reform Commission, the Ministry of Industry and Information Technology Industrialization Project, technological transformation projects, Hubei Province, Wuhan City major science and technology projects, key product industries Nearly 30 items, including the provincial-level enterprise technology center, cardiovascular drug engineering research center, and school-industry co-construction R&D center and other platforms. Yang Jinkui, chairman of Shandong Yinhe Biotechnology Co., Ltd., and Wang Chaodong, chairman of Wuhan Qirui Pharmaceuticals, witnessed the signing ceremony. At the signing ceremony of this strategic cooperation, Shandong Galaxy Bio-Tech Co., Ltd. and Shanghai Meiyue Bio-Technology Development Co., Ltd. have established a new type of strategic cooperative relationship, and both parties will carry out in-depth exchanges and cooperation in the areas of pharmaceutical product research and development and biotechnology.
Galaxy will conduct trial, verification, trial production and production of ornithine hydrochloride (intermediates), daptomycin (medical raw materials) and other products. Galaxy will upgrade from a cosmetic and food-grade raw material production enterprise to a pharmaceutical-grade raw material production enterprise.